Evidence map›Paper›PMID 41948517›Full record

ArticleDose-response : a publication of International Hormesis Society

Comparison of the Efficacy of Different Doses of Filgotinib in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on the RCTs.

Xia Ye, Sidong Zhu, Dongying Wang, Lifeng Hu, Yudie Li, Qingping Wu, Jingqi Chen, Bangsheng Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xia YeGeneral Family Medicine, Ningbo Hospital of Integrated Traditional Chinese and Western Medicine, Ningbo, Zhejiang, China.
Sidong ZhuThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejian, China.
Dongying WangThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejian, China.
Lifeng HuEmergency Department, Ningbo Yinzhou No. 3 Hospital, Ningbo, Zhejiang, China.
Yudie LiEmergency Department, Ningbo Yinzhou No. 3 Hospital, Ningbo, Zhejiang, China.
Qingping WuThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejian, China.
Jingqi ChenThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejian, China.
Bangsheng ChenEmergency Medical Center, Ningbo Hospital of Integrated Traditional Chinese and Western Medicine, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0002-6428-8248

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study compared the efficacy of different doses of filgotinib (100 mg vs 200 mg) in the treatment of rheumatoid arthritis (RA). Methods: We conducted a systematic review of 4 electronic databases up to January 2025. Primary outcome measures included ACR20, ACR50, ACR70. Results: Five RCTs were included in this analysis, in which 2191 patients with RA were evaluated, 100 mg filgotinib was noninferior to 200 mg filgotinib in the efficacy of ACR20 (P = 0.33, RR = 0.96). However, 100 mg filgotinib was inferior to 200 mg filgotinib for RA when using ACR50 (P = 0.04, RR = 0.92) and ACR70 (P = 0.02, RR = 0.86) as outcome measures. At 24 weeks, 100 mg filgotinib was inferior to 200 mg filgotinib at ACR50 (P = 0.07, RR = 0.84), and there was no significant difference between 100 mg and 200 mg filgotinib at ACR70 (P = 0.54, RR =0.88). The 52-week results showed 100 mg filgotinib was inferior to 200 mg filgotinib at ACR70 (P = 0.01, RR = 0.86). Conclusion: Reduced dose filgotinib (100 mg) may be used as a potential treatment option for RA when treatment is required.

Indexed as

ACRefficacyfilgotinibmeta-analysisrheumatoid arthritisvolume reduction

Identifiers

PMID41948517
PMCPMC13051078

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.